CTVA on NYSE

Corteva

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons⁵

American agriculture company

$12.78 down 0.62 (4.66%)Price as of Oct 15, 2026 at 19:45 UTC

Last updated Oct 16, 2026.

Overview

Mar 15, 2018Founded¹

Compare with Dole plc, Fresh Del Monte Produce or Adecoagro, or pick any stock.

TickerCTVA on NYSE¹
IndustryPesticide and Other Agricultural Chemical Manufacturing, Soil Preparation, Planting, and Cultivating¹
HeadquartersWashington, D.C.¹
Founded inIndianapolis¹
Websitewww.corteva.com
Legal formDelaware corporation¹
Incorporated inDE⁶
Business address9330 Zionsville Road, Indianapolis, In 46268⁶
Filer categoryLarge accelerated filer⁶

See how the biggest companies compare on our leaderboards

Corteva, Inc. (also known as Corteva Agriscience) is an American company devoted to products for seeds and crop protection, including herbicides, insecticides, fungicides, and biologicals (natural herbicides) that are sold in 110 countries. The company's name combines "cor" (Latin for "heart") with "teva" (the Hebrew word for nature). It is headquartered in Indianapolis, Indiana. Its primary brand is Pioneer Hi-Bred International.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

6.3%Net margin⁸

2.9%Revenue growth, 2025⁸

4.5%Return on equity⁸

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Seed brought in 57% of the revenue Corteva broke down this way in fiscal 2025.

Seed$9.9B⁸57%up 4% from 2024
Crop Protection$7.5B⁸43%up 2% from 2024

Business segments by year

Business segments	2023	2024	2025
Seed	$9.5B	$9.5B	$9.9B
Crop Protection	$7.8B	$7.4B	$7.5B

Regions

United States brought in 41% of the revenue Corteva broke down this way in fiscal 2025.

United States$8.3B⁸41%up 5% from 2024
Latin America$3.9B⁸19%up 4% from 2024
EMEA$3.1B⁸15%down 0% from 2024
Brazil$2.9B⁸14%up 11% from 2024
Asia Pacific$1.3B⁸7%down 1% from 2024
Canada$755.0M⁸4%down 5% from 2024

Regions by year

Regions	2023	2024	2025
United States	$7.8B	$7.9B	$8.3B
Latin America	$3.9B	$3.8B	$3.9B
EMEA	$3.4B	$3.1B	$3.1B
Brazil	$2.5B	$2.6B	$2.9B
Asia Pacific	$1.4B	$1.3B	$1.3B
Canada	$807.0M	$794.0M	$755.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and admin

Cost of revenue53¢$9.2B
Research and development8¢$1.5B
Selling, general and admin20¢$3.5B
Other costs10¢$1.7B
Income tax3¢$484.0M
Profit6¢$1.1B

Out of $17.4B in revenue.⁸

Where each dollar of operating cash went, fiscal 2025

Dividends paidShare buybacksKept or used elsewhere

Dividends paid14¢$475.0M
Share buybacks31¢$1.1B
Kept or used elsewhere55¢$1.9B

Out of $3.4B of cash from operations.⁸

Financial statements

Revenue⁹¹⁰¹¹¹²⁸$17.4B in 2025+26% since 2019

Net income⁹¹⁰¹¹¹²⁸$1.1B in 2025

Every line of the income statement in the latest annual report, as filed.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Net Sales	$17.4B	$16.9B	$17.2B
Cost of Goods Sold	$9.2B	$9.5B	$9.9B
Research and Development Expense	$1.5B	$1.4B	$1.3B
Selling, General and Administrative Expense	$3.5B	$3.2B	$3.2B
Amortization of Intangibles	$644.0M	$685.0M	$683.0M
Restructuring and asset related charges - net	$146.0M	$288.0M	$336.0M
Business Separation Costs	$35.0M	$0	$0
Other income (expense) - net	-$570.0M	-$300.0M	-$448.0M
Interest Expense	$180.0M	$233.0M	$233.0M
Income (loss) from continuing operations before income taxes	$1.7B	$1.3B	$1.1B
Provision for (benefit from) income taxes on continuing operations	$484.0M	$412.0M	$152.0M
Income (loss) from continuing operations after income taxes	$1.2B	$863.0M	$941.0M
Income (loss) from discontinued operations after income taxes	-$99.0M	$56.0M	-$194.0M
Net income (loss)	$1.1B	$919.0M	$747.0M
Net income (loss) attributable to noncontrolling interests	$11.0M	$12.0M	$12.0M
Net Income (Loss) attributable to Company	$1.1B	$907.0M	$735.0M
Basic earnings (loss) per share of common stock from continuing operations	$2	$1	$1
Basic earnings (loss) per share of common stock from discontinued operations	-$0	$0	-$0
Basic earnings (loss) per share of common stock	$1.60	$1.31	$1.04
Diluted earnings (loss) per share of common stock from continuing operations	$2	$1	$1
Diluted earnings (loss) per share of common stock from discontinued operations	-$0	$0	-$0
Diluted earnings (loss) per share of common stock	$1.60	$1.30	$1.03

Total assets¹⁵⁹¹⁰¹¹¹²⁸$42.8B in 2025+1% since 2019

Shareholders’ equity¹⁵⁹¹⁰¹¹¹²⁸$24.1B in 2025−1% since 2019

Cash¹⁵⁹¹⁰¹¹¹²⁸$4.5B in 2025+156% since 2019

Every line of the balance sheet in the latest annual report, as filed.⁸

Period ending	2026-01-31	2025-12-31	2024-12-31
Cash and Cash Equivalents		$4.5B	$3.1B
Marketable Securities		$9.0M	$63.0M
Accounts and notes receivable - net		$6.4B	$5.7B
Inventories		$5.7B	$5.4B
Other current assets		$767.0M	$820.0M
Total current assets		$17.3B	$15.1B
Investments in nonconsolidated affiliates		$160.0M	$134.0M
Property, Plant and Equipment		$9.6B	$9.1B
Less: Accumulated Depreciation		$5.3B	$5.0B
Net Property, Plant and Equipment		$4.2B	$4.1B
Goodwill		$10.5B	$10.4B
Other intangible assets		$8.3B	$8.9B
Deferred Income Taxes		$320.0M	$401.0M
Other Assets		$2.0B	$1.8B
Total Assets		$42.8B	$40.8B
Short-term borrowings and finance lease obligations		$894.0M	$750.0M
Accounts Payable		$4.4B	$4.0B
Income Taxes Payable		$155.0M	$207.0M
Deferred Revenue		$3.6B	$3.3B
Accrued and other current liabilities		$3.1B	$2.1B
Total current liabilities		$12.1B	$10.4B
Long-term Debt		$1.7B	$2.0B
Deferred Income Tax Liabilities		$251.0M	$478.0M
Pension and other post employment benefits - noncurrent		$2.4B	$2.3B
Other noncurrent obligations		$2.0B	$1.7B
Total Noncurrent Liabilities		$6.3B	$6.4B
Common Stock, Shares, Issued		672.2M shares	685.6M shares
Common stock		$7.0M	$7.0M
Additional Paid in Capital		$27.0B	$27.2B
Retained earnings (accumulated deficit)		-$67.0M	$55.0M
Accumulated other comprehensive income (loss)		-$2.8B	-$3.5B
Total stockholders' equity attributable to the company		$24.1B	$23.8B
Noncontrolling Interests		$242.0M	$241.0M
Total Equity		$24.4B	$24.0B
Total Liabilities and Equity		$42.8B	$40.8B
Common Stock, Par Value	$0.01	$0.01	$0.01
Common Stock, Shares Authorized		1.7B shares	1.7B shares
Common Stock, Shares, Outstanding		672.2M shares	685.6M shares

Cash from operations⁹¹⁰¹¹¹²⁸$3.4B in 2025+218% since 2019

Dividends paid⁹¹⁰¹¹¹²⁸$475.0M in 2025

Share buybacks⁹¹⁰¹¹¹²⁸$1.1B in 2025+4184% since 2019

Every line of the cash flow in the latest annual report, as filed.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income (loss)	$1.1B	$919.0M	$747.0M
(Income) Loss from Discontinued Operations, after income taxes	$99.0M	-$56.0M	$194.0M
Depreciation and amortization	$1.2B	$1.2B	$1.2B
Provision for (benefit from) deferred income tax	-$41.0M	-$365.0M	-$438.0M
Net periodic pension and OPEB (benefit) cost, net	$36.0M	$160.0M	$138.0M
Pension and OPEB contributions	-$136.0M	-$151.0M	-$149.0M
Net (gain) loss on sales of property, businesses, consolidated companies and investments	-$41.0M	-$17.0M	-$22.0M
Restructuring and Asset Related Charges - net	$146.0M	$288.0M	$336.0M
Other net loss	$545.0M	$383.0M	$578.0M
Accounts and Notes Receivable	-$261.0M	-$705.0M	$358.0M
Inventories	-$35.0M	$1.1B	$57.0M
Accounts Payable	$231.0M	-$115.0M	-$663.0M
Deferred Revenue	$270.0M	-$86.0M	-$11.0M
Other Assets and Liabilities	$336.0M	-$296.0M	-$527.0M
Cash Provided by (Used for) Operating Activities - Continuing Operations	$3.5B	$2.3B	$1.8B
Cash Provided by (Used for) Operating Activities - Discontinued Operations	-$51.0M	-$151.0M	-$40.0M
Cash provided by (used for) operating activities	$3.4B	$2.1B	$1.8B
Capital expenditures	-$591.0M	-$597.0M	-$595.0M
Proceeds from Sales of property, businesses, and consolidated companies - net of cash divested	$54.0M	$5.0M	$57.0M
Acquisitions of businesses - Net of Cash Acquired	$0	$0	-$1.5B
Investments in and loans to nonconsolidated affiliates	-$20.0M	-$7.0M	-$32.0M
Purchases of investments	$0	-$144.0M	-$148.0M
Proceeds from Sale and Maturities of Investments	$135.0M	$130.0M	$147.0M
Payments for (Proceeds from) Hedge, Investing Activities	-$83.0M	$63.0M	$42.0M
Other investing activities - net	-$38.0M	-$39.0M	-$2.0M
Cash provided by (used for) investing activities	-$543.0M	-$589.0M	-$2.0B
Net Change in borrowings (less than 90 days)	$0	$53.0M	-$6.0M
Proceeds from Debt	$1.7B	$3.1B	$3.4B
Payments on Debt	-$1.9B	-$2.9B	-$2.3B
Repurchase of Common Stock	-$1.1B	-$1.0B	-$756.0M
Proceeds from Exercise of Stock Options	$88.0M	$60.0M	$31.0M
Dividends Paid to stockholders	-$475.0M	-$458.0M	-$439.0M
Other financing activities, net	-$45.0M	-$32.0M	-$49.0M
Cash provided by (used for) financing activities	-$1.6B	-$1.2B	-$99.0M
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	$84.0M	-$93.0M	-$143.0M
Increase (decrease) on cash, cash equivalents and restricted cash	$1.3B	$264.0M	-$460.0M
Interest, net of amounts capitalized	$191.0M	$244.0M	$234.0M
Income Taxes	$750.0M	$707.0M	$535.0M

Compare Corteva with another company

The story

After the merger of the Dow Chemical Company and DuPont to form DowDuPont in August 2017, Corteva was formed in March 2018 as a subsidiary handling the parent company's agriculture activities, which focused on seeds and crop protection. In June 2019, DowDuPont completed the corporate spin-off of the company and Corteva became a public company. Included in the spin-off was E. I. du Pont de Nemours and Company, the former corporate entity of DuPont which was designated as the predecessor to Corteva and was renamed to EIDP, Inc. in January 2023.

In March 2019, Corteva commissioned Charles River Laboratories to test its new fungicide on 36 beagles. Corteva argued that such testing is required by regulatory authorities but, after outrage from the Humane Society of the United States, the company agreed to stop the tests and release the animals to Michigan Humane for adoption.

In February 2020, Corteva ceased production of the pesticide chlorpyrifos due to declining sales after the product was linked to neurological problems in children and following bans in the European Union and some US states.

In March 2023, the company acquired Stoller Group, a maker of natural pesticides for $1.2 billion. It also acquired Symborg, an expert in microbiological technologies based in Murcia, Spain. This was part of an overall strategy to grow and strengthen an emerging biologicals product portfolio.

In November 2024, the company partnered with BP to develop a low carbon intensive bio-feedstock for the production of aviation biofuel. Also in November 2024, the company acquired the naming rights to the Indiana Farmers Coliseum at the Indiana State Fairgrounds. In 2025, the company introduced Forcivo, a fungicide for corn and soybeans containing flutriafol, azoxystrobin, and fluindapyr and targeting tar spot, southern rust, and frogeye leaf spot. In September 2025, the Wall Street Journal reported the company was exploring a breakup that would separate its seed and pesticide businesses. The company confirmed it planned to separate the businesses in October 2025. In May 2026, Corteva announced the name Vylor for its seed and genetics business.

From Wikipedia’s article on Corteva, shared under CC BY-SA 4.0.⁷

Leadership

Who has led Corteva, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chuck Magro2021–now

20202025

Chief executive officerChuck Magro Nov 1, 2021 to now¹

Products and brands

Copper hydroxide

Listed on Wikidata.¹

Subsidiaries and ownership

Subsidiaries

Pioneer Hi-Bred
EIDP since 2019

Former owners and parents

DowDuPont until Jun 1, 2019

From Wikidata.¹

Acquisitions

2019Acquired EIDP¹

Employees over time

202221,000¹

Controversies and legal

Legal issues

In July 2020, a U.S. appeals court ruled that Corteva can continue to sell Enlist Duo, which contains glyphosate and a salt of 2,4-D and choline, after environmentalists attempted to block sales of the chemical due to its claimed negative effects on plants and wildlife. However, the court ruled that the U.S. Environmental Protection Agency properly relied on studies that showed that the volatility of 2,4-D choline salt will not cause unreasonable harm to the environment.

In August 2022, Bayer sued Corteva for breach of contractual obligations related to the development and commercialization of E3 soybeans. Corteva then sued Bayer, alleging that Bayer infringed upon its patents on a gene used in Enlist Corn, which is resistant to herbicides such as Roundup. In May 2025, the case was paused until the US Supreme Court considers whether to take up a separate patent-related case.

In September 2022, the Federal Trade Commission sued Syngenta and Corteva, challenging certain US-based discount programs that allegedly block and restrict generic competition from pesticide markets. In January 2024, a federal judge denied a motion to dismiss the lawsuit.